Kevin R. Lind's most recent trade in Avalo Therapeutics Inc was a trade of 848 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Dec. 31, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Avalo Therapeutics Inc | Kevin R. Lind | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2025 | 848 | 848 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Kevin R. Lind | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2025 | 40,200 | 40,200 | - | - | Stock Option (Right to Buy) | |
| Longboard Pharmaceuticals Inc | Kevin R. Lind | Director, President and CEO | 02 Dec 2024 | 363,740 | 0 | - | 60 | 21,824,400 | Common Stock | |
| Longboard Pharmaceuticals Inc | Kevin R. Lind | Director, President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Dec 2024 | 332,134 | 0 | - | - | Employee Stock Option (right to buy) | |
| Longboard Pharmaceuticals Inc | Kevin R. Lind | Director, President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Dec 2024 | 325,850 | 0 | - | - | Employee Stock Option (right to buy) | |
| Longboard Pharmaceuticals Inc | Kevin R. Lind | Director, President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Dec 2024 | 255,377 | 0 | - | - | Employee Stock Option (right to buy) | |
| Longboard Pharmaceuticals Inc | Kevin R. Lind | Director, President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Dec 2024 | 192,783 | 0 | - | - | Employee Stock Option (right to buy) | |
| Longboard Pharmaceuticals Inc | Kevin R. Lind | Director, President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Dec 2024 | 22,000 | 0 | - | - | Restricted Stock Unit | |
| Longboard Pharmaceuticals Inc | Kevin R. Lind | Director, CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Nov 2024 | 80,000 | 363,740 | - | 0 | Common Stock | |
| Longboard Pharmaceuticals Inc | Kevin R. Lind | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2024 | 12,808 | 255,377 | - | - | Stock Option (Right to Buy) | |
| Longboard Pharmaceuticals Inc | Kevin R. Lind | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.12 per share. | 13 Nov 2024 | 12,808 | 443,740 | - | 3.1 | 40,002 | Common Stock |
| Longboard Pharmaceuticals Inc | Kevin R. Lind | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Oct 2024 | 22,000 | 22,000 | - | - | Retention Restricted Stock Units | |
| Longboard Pharmaceuticals Inc | Kevin R. Lind | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.12 per share. | 12 Aug 2024 | 80,265 | 428,715 | - | 3.1 | 250,684 | Common Stock |
| Longboard Pharmaceuticals Inc | Kevin R. Lind | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2024 | 80,265 | 268,185 | - | - | Stock Option (Right to Buy) | |
| Longboard Pharmaceuticals Inc | Kevin R. Lind | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2024 | 2,217 | 192,783 | - | - | Stock Option (Right to Buy) | |
| Longboard Pharmaceuticals Inc | Kevin R. Lind | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.20 per share. | 12 Aug 2024 | 2,217 | 430,932 | - | 4.2 | 9,311 | Common Stock |
| Longboard Pharmaceuticals Inc | R. Lind Kevin | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 332,134 | 332,134 | - | - | Stock Option (Right to Buy) | |
| Longboard Pharmaceuticals Inc | Kevin R. Lind | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 325,850 | 325,850 | - | - | Stock Option (Right to Buy) |